Found 241 clinical trials
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)
Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3
- 46 views
- 26 Jan, 2021
- 12 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Pediatrics/Neonatology
-
Currently Recruiting
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma
molecule multi-kinase inhibitor of VEGFR, PDGFR and RAF with demonstrated activity in the treatment of renal cell cancer (9). Preclinical studies suggest that the combination of Sorafenib with
- 13 views
- 07 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer ALTER-L029
Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer
- 0 views
- 23 Jan, 2021
- 4 locations
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC). In chemotherapy, docetaxel and pemetrexed produced similar treatment efficacy outcomes, while pemetrexed had a better tolerability. In recent analysis of pemetrexed clinical studies, a strong treatment-by-histology interaction in overall survival and progression …
- 9 views
- 07 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
The aim of this study is to demonstrate that the use of Gleevec in initially non-resectable gastrointestinal stromal tumors can lead to allow complete resection in 20% of cases.
- 6 views
- 07 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell mediator release, unresponsive to optimal symptomatic treatment.
- 0 views
- 26 Jan, 2021
- 7 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy
The primary objective of this study is to evaluate the tolerability and the maximum tolerated dose of Conformal or Intensity-Modulated Radiotherapy when given in combination with gefitinib 250mg in Chinese patients with IIIB or IV NSCLC after failure of platinum-based chemotherapy. Secondary objectives of the study are to obtain the …
- 1 views
- 07 Nov, 2020
- 1 location
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC
In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.
- 0 views
- 23 Jan, 2021
- 1 location
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
100s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
Treatment Modification Based on Early Assessment of CML Patients
The investigators will check the feasibility of using early molecular response for making treatment decisions. Patients diagnosed with chronic myeloid leukemia will commence imatinib treatment. After 3 months of treatment their response will be assessed. If molecular response would be less the 10% (BCR-ABL1/ABL ISI >10%)imatinib therapy will be stopped …
- 5 views
- 08 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the anti VEGFR-TKI and decrease the related toxicity of the combination therapy.
- 0 views
- 27 Jan, 2021
- 20 locations